Filter by ContentType
Revolutionizing the treatment of cancer with allogeneic CAR-T cell therapy
Cokey Nguyen
13 November 2024
Expert Insight
Patient-specific factors that could influence gene therapy outcomes in sickle cell disease
Abdulrahman Alsultan, Jaap Jan Boelens
02 September 2024
Expert Insight
Checkpoint on I–O resistance: lessons learnt & future perspectives
R Stewart, M L Miller, A Camelo et al
28 May 2023
Expert Insight
Strategic partnering to enable cell therapy commercialization
02 October 2022
Expert Insight
Preclinical models for development of immune–oncology therapies
Y Wang, S E Shelton, G Kastrunes et al
27 September 2022
Expert Insight
Stabilizing DNA–PEI complexes improves scalability of suspension lentiviral viral vector and AAV processes
B Olden, H Seo, R Barnes et al
28 August 2022
Expert Insight
Site specific responses to immune checkpoint inhibitors
Clinton Wu, Adil Daud
08 June 2022
Expert Insight
Implications of liver metastasis for cancer immunotherapy
James C Lee
26 May 2022
Expert Insight
Combination immune therapy in melanoma: a tale of two therapies
Gregory A Daniels
15 May 2022
Expert Insight
Unleashing the full potential of cell therapy through RNA engineering
Metin Kurtoglu
11 May 2022
Expert Insight
Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies
Karin Hägerbrand, Peter Ellmark
11 April 2022
Expert Insight
A need to update paradigms for myeloid cells within the tumor microenvironment to advance immunotherapy
Michelle Kinder, PhD
21 January 2022
Expert Insight
Umbilical cord blood NK cells offer multiple advantages for cancer immunotherapy: lessons learned from Glycostem’s orphan drug oNKord®
Volker Huppert
14 January 2022
Expert Insight
Considerations for the development of autologous CAR-T cell products
A Davidson, G Santiago Toledo, K Lilova et al
11 January 2022
Expert Insight
Antibody drug conjugates: accelerated approvals targeting oncology
Stuart Jamieson, Daniel Myatt, John Liddell
06 December 2021
Expert Insight
Control of continuous processes for production of biopharmaceutical products
Anurag Rathore, Saxena Nikita
29 November 2021
Expert Insight
Artificial intelligence: accelerating translational cell therapy development through computational methods for neoepitope discovery
M Chiriva-Internati, L Piccotti, L Zammataro et al
25 November 2021
Expert Insight
Next-generation DNA vectors: is the nS/MARt platform a viable alternative to viruses for autologous T-cell immunotherapy?
Matthias Bozza, Richard Harbottle
23 November 2021
Expert Insight
The use of artificial intelligence in immuno-oncology drug discovery: are we closing the gap?
Carlo Boutton, Maria Wendt
08 October 2021
Expert Insight
Advancement of precision oncology by integration of highly sensitive protein profiling technologies and patient-derived cell models for functional efficacy testing
Michael Pawlak, Markus Templin, Christian Schmees
05 August 2021
Expert Insight
Digital pathology for the identification of prognostic biomarkers in head and neck cancer
Rasha Abu-Eid, Frank James Ward
08 June 2021
Expert Insight